CILOXAN 0.3 % — DIN 01945270
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 0.3 % · NOVARTIS PHARMACEUTICALS CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is CILOXAN?
CILOXAN 0.3 % contains CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 0.3 %. It is listed in the Health Canada Drug Product Database under DIN 01945270, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 15-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CILOXAN used for?
CILOXAN® (ciprofloxacin ophthalmic solution) is indicated for the treatment of infections of the eye and its adnexae when caused by susceptible strains of Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae (Corneal Ulcers), Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus (Viridans group), Streptococcus pneumoniae, Haemophilus influenzae (Conjunctivitis). CILOXAN® (ciprofloxacin ophthalmic ointment) is indicated for the treatment of infections of the eye and its adnexae when caused by susceptible strains of Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis (Corneal Ulcers), Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus (Viridans group), Streptococcus pneumoniae, Haemophilus influenzae (Conjunctivitis). To reduce the development of drug-resistant bacteria and maintain the effectiveness of CILOXAN and other antibacterial drugs, CILOXAN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Ciprofloxacin cost around the world?
Ciprofloxacin is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 75 | 81 | SAR███.██ |
| South Africa | single exit price | 64 | 81 | ZAR███.██ |
| United States | acquisition | 5 | 52 | USD███.██ |
| Greece | producer price (ex-factory) | 39 | 39 | EUR███.██ |
| Sweden | AIP (pharmacy purchase price) | 10 | 38 | SEK███.██ |
| Bahrain | retail (max) | 20 | 31 | BHD███.██ |
| Romania | max producer price | 20 | 25 | RON███.██ |
| Australia | ex-manufacturer | 11 | 20 | AUD███.██ |
| United Kingdom | hospital | 7 | 7 | GBP███.██ |
| United Arab Emirates | public | 6 | 6 | AED███.██ |
| Hungary | producer price (ex-factory) | 6 | 6 | HUF███.██ |
| Czechia | max producer price (ex-factory) | 2 | 3 | CZK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
392 pack listings across 268 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Ciprofloxacin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.3 % |
|---|---|
| Dosage form | SOLUTION |
| Route | OPHTHALMIC |
| Pack configuration (monograph) | CILOXAN solution is available in 5 mL and 10 mL plastic DROP-TAINER® dispensers. CILOXAN ointment is available in 3.5 g metal ophthalmic ointment tubes. |
| Storage | Store in the carton at room temperature (2°C – 30°C). Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Ciprofloxacin |
|---|---|
| ATC code | S03AA07 |
| AHFS class | 52:04.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01945270 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1945270 |
| Brand name | CILOXAN |
| Generic / active ingredient | CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 0.3 % |
| Market authorization holder | NOVARTIS PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | S03AA07 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S03AA |
| Current status | MARKETED |
| Status date | 15-Oct-2018 |
| Original market date | 1992-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Ciprofloxacin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC S03AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Antiinfectives, Combinations | ANTIBIOTIC DROPS · ANTIBIOTIC EYE DROPS · NEOSPORIN EYE-EAR SOLUTION · OPTIMYXIN · +4 more | 9 | 3 | Yes |
| Ciprofloxacin | CILOXAN | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CILOXAN called?
The same molecule, Ciprofloxacin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ciprofloxacin Krka | Latin | Sweden |
| Ciprofloxacin Accord | Latin | Sweden |
| Ciprofloxacin Orion | Latin | Sweden |
| Omacip | Latin | Bahrain, Saudi Arabia |
| CIPROCIN | Latin | Bahrain, Saudi Arabia |
| Ciprofloxacin Hexal | Latin | Sweden |
| Ciprofloxacin SUN | Latin | Sweden |
| CIPROGEN | Latin | Bahrain, Saudi Arabia |
| APO-Ciprofloxacin | Latin | Australia |
| Ciprocina | Latin | South Africa |
| Ciprofloxacin Bluefish | Latin | Sweden |
| Ciprofloxacin Ebb | Latin | Sweden |
| Ciprofloxacin Sandoz | Latin | Australia |
| Ciprofloxacin Viatris | Latin | Sweden |
| CIPROFLOXACIN-WGR | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.